Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

BACKGROUND: Interleukin-5 (IL-5) antibodies represent a promising therapeutic option for patients with severe eosinophilic asthma. To date, no official treatment response criteria exist. In this study, simple criteria for treatment response applicable to all asthma patients were used to evaluate cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Drick, Nora, Seeliger, Benjamin, Welte, Tobias, Fuge, Jan, Suhling, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052600/
https://www.ncbi.nlm.nih.gov/pubmed/30021546
http://dx.doi.org/10.1186/s12890-018-0689-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052600/
https://www.ncbi.nlm.nih.gov/pubmed/30021546
http://dx.doi.org/10.1186/s12890-018-0689-2

Ejemplares similares